肯塔基州要求所有阿片类处方使用州处方药监测计划立法后加巴喷丁暴露趋势
该研究回顾性横断面分析了2012年1月1日至2015年12月31日报告至一家区域中毒中心的加巴喷丁暴露。加巴喷丁单药暴露从2012年39例增至2015年160例(共424例),含加巴喷丁的多药暴露从165例增至440例(共1321例),而同期该中心报告的总人类暴露下降。单药组9例(2%)出现重大医学结局、3例(1%)死亡;多药组76例(6%)出现重大医学结局、12例(1%)死亡,近半数多药暴露需入住ICU。多数暴露为故意摄入,具体为疑似自杀。暴露增加与肯塔基州实施处方阿片类改革立法时间吻合。作者鼓励临床医生无论暴露类型均致电当地中毒中心,以有效监测和评估暴露趋势。
要点
- 加巴喷丁单药暴露从2012年39例增至2015年160例(共424例),含加巴喷丁多药暴露从165例增至440例(共1321例),而同期区域中毒中心总人类暴露下降。
- 加巴喷丁单药组9例(2%)出现重大医学结局、3例(1%)死亡;多药组76例(6%)出现重大医学结局、12例(1%)死亡。
- 含加巴喷丁的多药暴露近半数需入住ICU,提示多药共暴露患者病情更重。
- 多数加巴喷丁单药及多药暴露为故意摄入,具体为疑似自杀。
- 加巴喷丁暴露增加与肯塔基州实施处方阿片类改革立法时间吻合;作者鼓励无论暴露类型均致电当地中毒中心以监测暴露趋势。
适用人群与场景
- 2012年1月1日至2015年12月31日报告至一家区域中毒中心的加巴喷丁单药暴露及含加巴喷丁的多药暴露病例。
研究设计与关键结果
- 研究类型为回顾性横断面 review,数据来源为一家区域中毒中心2012年1月1日至2015年12月31日报告的暴露,主要结局为加巴喷丁单药暴露数和含加巴喷丁多药暴露数。
- 加巴喷丁单药暴露共424例,从2012年39例增至2015年160例;含加巴喷丁多药暴露共1321例,从2012年165例增至2015年440例;同期该区域中毒中心报告的总人类暴露下降。
- 加巴喷丁单药组9例(2%)出现重大医学结局、3例(1%)死亡;多药组76例(6%)出现重大医学结局、12例(1%)死亡。
- 含加巴喷丁的多药暴露近半数需入住ICU。
- 加巴喷丁单药及多药暴露多数为故意摄入,具体为疑似自杀;暴露增加与肯塔基州实施处方阿片类改革立法时间吻合。
证据类型、等级与局限
- 证据类型:回顾性横断面研究,单家区域中毒中心数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者鼓励临床医生无论暴露类型均致电当地中毒中心,以有效监测和评估暴露趋势。
- 原文未据此给出其他推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Gabapentin is a gamma-aminobutyric acid (GABA) analog approved by the Food and Drug Administration (FDA) for partial seizures and post-herpetic neuralgia. Due to its wide therapeutic window and minimal adverse effects, it is frequently prescribed for additional off-label uses. The purpose of this study was to characterize the number, exposure reason, medical outcomes, and disposition of gabapentin exposures reported to one regional poison control center (PCC).
METHODS: A retrospective cross-sectional review of exposures reported to one regional PCC was performed from January 1, 2012 to December 31, 2015. The primary outcomes were the number of gabapentin-only exposures and multi-agent exposures including gabapentin reported. Exposure reason, medical outcome, and disposition were identified for each exposure.
RESULTS: There were 424 gabapentin-only exposures during the study period. The number of exposures increased each year, from 39 in 2012 to 160 in 2015. There were 1321 multi-agent exposures that included gabapentin. These exposures increased from 165 in 2012 to 440 in 2015. Comparatively, total human exposures reported to the regional PCC decreased during the study period. The majority of gabapentin-only and multi-agent exposures was intentional versus unintentional. Nine patients (2%) had a major medical outcome and three patients (1%) died in the gabapentin-only group. Comparatively, 76 patients (6%) had a major medical outcome and 12 patients (1%) died in the multi-agent group. Almost half of the multi-agent exposures required admission to the intensive care unit (ICU).
CONCLUSIONS: Both gabapentin-only and multi-agent exposures increased significantly from 2012 to 2015, with the majority of cases intentional ingestion, specifically suspected suicide. The increased number of gabapentin exposures coincided with Kentucky's implementation of prescription opioid reform legislation. Providers are encouraged to call their local PCC, regardless of exposure type, to effectively monitor and evaluate exposure trends.
参考来源
- Faryar KA, Webb AN, Bhandari B, et al. Trending gabapentin exposures in Kentucky after legislation requiring use of the state prescription drug monitoring program for all opioid prescriptions. Clin Toxicol (Phila). 2019. PMID: 30676102. doi:10.1080/15563650.2018.1538518
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。